No evidence for association of inherited variation in genes involved in mitosis and percent mammographic density.

Abstract:

INTRODUCTION:Increased mammographic breast density is one of the strongest risk factors for breast cancer. While two-thirds of the variation in mammographic density appears to be genetically influenced, few variants have been identified. We examined the association of inherited variation in genes from pathways that mediate cell division with percent mammographic density (PMD) adjusted for age, body mass index (BMI) and postmenopausal hormones, in two studies of healthy postmenopausal women. METHODS:We investigated 2,058 single nucleotide polymorphisms (SNPs) in 378 genes involved in regulation of mitosis for associations with adjusted PMD among 484 unaffected postmenopausal controls (without breast cancer) from the Mayo Clinic Breast Cancer Study (MCBCS) and replicated the findings in postmenopausal controls (n = 726) from the Singapore and Sweden Breast Cancer Study (SASBAC) study. PMD was assessed in both studies by a computer-thresholding method (Cumulus) and linear regression approaches were used to assess the association of SNPs and PMD, adjusted for age, BMI and postmenopausal hormones. A P-value threshold of 4.2 × 10-5 based on a Bonferroni correction of effective number of independent tests was used for statistical significance. Further, a pathway-level analysis was conducted of all 378 genes using the self-contained gene-set analysis method GLOSSI. RESULTS:A variant in PRPF4, rs10733604, was significantly associated with adjusted PMD in the MCBCS (P = 2.7 × 10-7), otherwise, no single SNP was associated with PMD. Additionally, the pathway analysis provided no evidence of enrichment in the number of associations observed between SNPs in the mitotic genes and PMD (P = 0.60). We evaluated rs10733604 (PRPF4), and 73 other SNPs at P < 0.05 from 51 genes in the SASBAC study. There was no evidence of an association of rs10733604 (PRPF4) with adjusted PMD in SASBAC (P = 0.23). There were, however, consistent associations (P < 0.05) of variants at the putative locus, LOC375190, Aurora B kinase (AURKB), and Mini-chromosome maintenance complex component 3 (MCM3) with adjusted PMD, although these were not statistically significant. CONCLUSIONS:Our findings do not support a role of inherited variation in genes involved in regulation of cell division and adjusted percent mammographic density in postmenopausal women.

journal_name

Breast Cancer Res

authors

Vachon CM,Li J,Scott CG,Hall P,Czene K,Wang X,Liu J,Fredericksen ZS,Rider DN,Wu FF,Olson JE,Cunningham JM,Stevens KN,Sellers TA,Pankratz SV,Couch FJ

doi

10.1186/bcr3088

subject

Has Abstract

pub_date

2012-01-07 00:00:00

pages

R7

issue

1

eissn

1465-5411

issn

1465-542X

pii

bcr3088

journal_volume

14

pub_type

杂志文章
  • Breast cancer risk perception: what do we know and understand?

    abstract::Women's perceptions of breast cancer risk are largely inaccurate and are often associated with high levels of anxiety about cancer. There are interesting cultural differences that are not well researched. Genetic risk counselling significantly improves accuracy of women's perceptions of risk, but not necessarily to th...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr83

    authors: Hopwood P

    更新日期:2000-01-01 00:00:00

  • CRIPTO antagonist ALK4L75A-Fc inhibits breast cancer cell plasticity and adaptation to stress.

    abstract:BACKGROUND:CRIPTO is a multi-functional signaling protein that promotes stemness and oncogenesis. We previously developed a CRIPTO antagonist, ALK4L75A-Fc, and showed that it causes loss of the stem cell phenotype in normal mammary epithelia suggesting it may similarly inhibit CRIPTO-dependent plasticity in breast canc...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01361-z

    authors: Balcioglu O,Heinz RE,Freeman DW,Gates BL,Hagos BM,Booker E,Mirzaei Mehrabad E,Diesen HT,Bhakta K,Ranganathan S,Kachi M,Leblanc M,Gray PC,Spike BT

    更新日期:2020-11-13 00:00:00

  • Measuring proliferation in breast cancer: practicalities and applications.

    abstract::Various methods are available for the measurement of proliferation rates in tumours, including mitotic counts, estimation of the fraction of cells in S-phase of the cell cycle and immunohistochemistry of proliferation-associated antigens. The evidence, advantages and disadvantages for each of these methods along with ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr1618

    authors: Beresford MJ,Wilson GD,Makris A

    更新日期:2006-01-01 00:00:00

  • The clinical and functional significance of c-Met in breast cancer: a review.

    abstract::c-Met is a receptor tyrosine kinase that upon binding of its ligand, hepatocyte growth factor (HGF), activates downstream pathways with diverse cellular functions that are important in organ development and cancer progression. Anomalous c-Met signalling has been described in a variety of cancer types, and the receptor...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/s13058-015-0547-6

    authors: Ho-Yen CM,Jones JL,Kermorgant S

    更新日期:2015-04-08 00:00:00

  • Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry.

    abstract:BACKGROUND:Approximately 100 common breast cancer susceptibility alleles have been identified in genome-wide association studies (GWAS). The utility of these variants in breast cancer risk prediction models has not been evaluated adequately in women of Asian ancestry. METHODS:We evaluated 88 breast cancer risk variant...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-016-0786-1

    authors: Wen W,Shu XO,Guo X,Cai Q,Long J,Bolla MK,Michailidou K,Dennis J,Wang Q,Gao YT,Zheng Y,Dunning AM,García-Closas M,Brennan P,Chen ST,Choi JY,Hartman M,Ito H,Lophatananon A,Matsuo K,Miao H,Muir K,Sangrajrang S,

    更新日期:2016-12-08 00:00:00

  • More breast cancer genes?

    abstract::A new gene associated with a high risk of breast cancer, termed BRCAX, may exist on chromosome 13q. Tumours from multicase Nordic breast cancer families, in which mutations in BRCA1 and BRCA2 had been excluded, were analyzed using comparative genomic hybridization in order to identify a region of interest, which was a...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr290

    authors: Hopper JL

    更新日期:2001-01-01 00:00:00

  • Integrin-mediated resistance to epidermal growth factor receptor-targeted therapy: an inflammatory situation.

    abstract::Targeting the function of epidermal growth factor receptor (EGFR) has failed as an effective clinical option for breast cancer. Understanding the drivers of inherent resistance has been a challenge. One possible mechanism is the acquisition of stem-like properties through the process of epithelial-mesenchymal transiti...

    journal_title:Breast cancer research : BCR

    pub_type: 评论,杂志文章

    doi:10.1186/s13058-014-0448-0

    authors: Brown WS,Wendt MK

    更新日期:2014-09-23 00:00:00

  • Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.

    abstract:BACKGROUND:Controversies exist as to whether the genetic polymorphisms of the enzymes responsible for the metabolism of tamoxifen can predict breast cancer outcome in patients using adjuvant tamoxifen. Direct measurement of concentrations of active tamoxifen metabolites in serum may be a more biological plausible and r...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-017-0916-4

    authors: Helland T,Henne N,Bifulco E,Naume B,Borgen E,Kristensen VN,Kvaløy JT,Lash TL,Alnæs GIG,van Schaik RH,Janssen EAM,Hustad S,Lien EA,Mellgren G,Søiland H

    更新日期:2017-11-28 00:00:00

  • Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts.

    abstract:INTRODUCTION:Rapamycin, an inhibitor of the serine/threonine kinase target of rapamycin, induces G1 arrest and/or apoptosis. Although rapamycin and its analogues are attractive candidates for cancer therapy, their sensitivities with respect to growth inhibition differ markedly among various cancer cells. Using human br...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1344

    authors: Kasukabe T,Okabe-Kado J,Kato N,Sassa T,Honma Y

    更新日期:2005-01-01 00:00:00

  • Prospective validation of the NCI Breast Cancer Risk Assessment Tool (Gail Model) on 40,000 Australian women.

    abstract:BACKGROUND:There is a growing interest in delivering more personalised, risk-based breast cancer screening protocols. This requires population-level validation of practical models that can stratify women into breast cancer risk groups. Few studies have evaluated the Gail model (NCI Breast Cancer Risk Assessment Tool) i...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-018-1084-x

    authors: Nickson C,Procopio P,Velentzis LS,Carr S,Devereux L,Mann GB,James P,Lee G,Wellard C,Campbell I

    更新日期:2018-12-20 00:00:00

  • Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer.

    abstract:INTRODUCTION:Hypoxia-inducible factor (HIF)-1alpha levels in invasive breast carcinoma have been shown to be an adverse prognostic indicator. Cellular HIF-1alpha activity is regulated by factor-inhibiting hypoxia-inducible factor 1 (FIH-1). In hypoxia, FIH-1 hydroxylation of Asn803 within the C-terminal transactivation...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1838

    authors: Tan EY,Campo L,Han C,Turley H,Pezzella F,Gatter KC,Harris AL,Fox SB

    更新日期:2007-01-01 00:00:00

  • Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.

    abstract::Recent studies indicate that constitutive signaling through the phosphatidylinositol 3'-kinase (PI3K) pathway is a cause of treatment resistance in breast cancer patients. This implies that patients with tumors that exhibit aberrant PI3K signaling may benefit from targeted pathway inhibitors. The first agents to make ...

    journal_title:Breast cancer research : BCR

    pub_type: 评论,杂志文章

    doi:10.1186/bcr1307

    authors: Crowder RJ,Ellis MJ

    更新日期:2005-01-01 00:00:00

  • Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.

    abstract:INTRODUCTION:Pre-clinical data suggest p53-dependent anthracycline-induced apoptosis and p53-independent taxane activity. However, dedicated clinical research has not defined a predictive role for TP53 gene mutations. The aim of the current study was to retrospectively explore the prognosis and predictive values of TP5...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,随机对照试验

    doi:10.1186/bcr3179

    authors: Fernández-Cuesta L,Oakman C,Falagan-Lotsch P,Smoth KS,Quinaux E,Buyse M,Dolci MS,Azambuja ED,Hainaut P,Dell'orto P,Larsimont D,Francis PA,Crown J,Piccart-Gebhart M,Viale G,Leo AD,Olivier M

    更新日期:2012-05-02 00:00:00

  • Tracking the genomic evolution of breast cancer metastasis.

    abstract::Therapeutic choices for metastatic tumors are, in most cases, based upon the histological and molecular analysis of the corresponding primary tumor. Understanding whether and to what extent the genomic landscape of metastasis differs from the tumors from which they originated is critical yet largely unknown. A recent ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2469

    authors: Zecchin D,Bardelli A

    更新日期:2010-01-01 00:00:00

  • Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors.

    abstract:INTRODUCTION:Aromatase inhibitor-associated arthralgia (AIAA) is a common and often debilitating symptom in breast cancer survivors. Since joint symptoms have been related to estrogen deprivation through the menopausal transition, we hypothesized that genetic polymorphisms in CYP19A1, the final enzyme in estrogen synth...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2813

    authors: Mao JJ,Su HI,Feng R,Donelson ML,Aplenc R,Rebbeck TR,Stanczyk F,DeMichele A

    更新日期:2011-01-20 00:00:00

  • Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.

    abstract:INTRODUCTION:Triple-negative breast cancer does not express estrogen and progesterone receptors, and no overexpression/amplification of the HER2-neu gene occurs. Therefore, this subtype of breast cancer lacks the benefits of specific therapies that target these receptors. Today chemotherapy is the only systematic thera...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2606

    authors: Gründker C,Föst C,Fister S,Nolte N,Günthert AR,Emons G

    更新日期:2010-01-01 00:00:00

  • Plasma levels of leptin and mammographic density among postmenopausal women: a cross-sectional study.

    abstract:INTRODUCTION:Obesity has been linked to increased risk of breast cancer in postmenopausal women. Increased peripheral production of estrogens has been regarded as the main cause for this association, but other features of increased body fat mass may also play a part. Leptin is a protein produced mainly by adipose tissu...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1603

    authors: Stuedal A,Ursin G,Veierød MB,Bremnes Y,Reseland JE,Drevon CA,Gram IT

    更新日期:2006-01-01 00:00:00

  • Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions.

    abstract::A series of recent studies have demonstrated that the retinoblastoma tumor suppressor (RB) pathway plays a critical role in multiple clinically relevant aspects of breast cancer biology, spanning early stage lesions to targeted treatment of metastatic disease. In ductal carcinoma in situ, multiple groups have shown th...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr3652

    authors: Witkiewicz AK,Knudsen ES

    更新日期:2014-05-07 00:00:00

  • 17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2.

    abstract:INTRODUCTION:17-allyamino-17-demethoxygeldanamycin (17-AAG), a small molecule inhibitor of Hsp90, is currently in clinical trials in breast cancer. However, 17-AAG treatment often results in inhibition of tumor growth rather than shrinkage, making detection of response a challenge. Magnetic resonance spectroscopy (MRS)...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2729

    authors: Brandes AH,Ward CS,Ronen SM

    更新日期:2010-01-01 00:00:00

  • Vitamin D receptor expression in invasive breast tumors and breast cancer survival.

    abstract:BACKGROUND:Vitamin D has been suggested to prevent and improve the prognosis of several cancers, including breast cancer. We have previously shown a U-shaped association between pre-diagnostic serum levels of vitamin D and risk of breast cancer-related death, with poor survival in patients with the lowest and the highe...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-019-1169-1

    authors: Huss L,Butt ST,Borgquist S,Elebro K,Sandsveden M,Rosendahl A,Manjer J

    更新日期:2019-07-29 00:00:00

  • Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO).

    abstract:INTRODUCTION:Mutations in BRCA1 and BRCA2 confer a high risk of breast cancer (BC), but the magnitude of this risk seems to vary according to the study and various factors. Although controversial, there are data to support the hypothesis of allelic risk heterogeneity. METHODS:We assessed variation in BC risk according...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3218

    authors: Lecarpentier J,Noguès C,Mouret-Fourme E,Gauthier-Villars M,Lasset C,Fricker JP,Caron O,Stoppa-Lyonnet D,Berthet P,Faivre L,Bonadona V,Buecher B,Coupier I,Gladieff L,Gesta P,Eisinger F,Frénay M,Luporsi E,Lortholary A,

    更新日期:2012-07-03 00:00:00

  • Clinical trial update: National Cancer Institute of Canada.

    abstract::The Breast Cancer Site Group (BCSG) of the National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG) has conducted a wide variety of clinical trials focussing on large phase III trials of adjuvant chemotherapy, adjuvant hormonal therapy, and optimal delivery of adjuvant radiation therapy. The Group has al...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr979

    authors: Pritchard K,Whelan T

    更新日期:2005-01-01 00:00:00

  • Relevance of PTEN loss in brain metastasis formation in breast cancer patients.

    abstract:INTRODUCTION:With the improvement of therapeutic options for the treatment of breast cancer, the development of brain metastases has become a major limitation to life expectancy in many patients. Therefore, our aim was to identify molecular markers associated with the development of brain metastases in breast cancer. ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3150

    authors: Wikman H,Lamszus K,Detels N,Uslar L,Wrage M,Benner C,Hohensee I,Ylstra B,Eylmann K,Zapatka M,Sauter G,Kemming D,Glatzel M,Müller V,Westphal M,Pantel K

    更新日期:2012-03-19 00:00:00

  • HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer.

    abstract:BACKGROUND:Tumor-derived extracellular vesicles (tdEVs) and circulating tumor cells (CTCs) in the blood of metastatic cancer patients associate with poor outcomes. In this study, we explored the human epidermal growth factor receptor 2 (HER2) expression on CTCs and tdEVs of metastatic breast cancer patients. METHODS:B...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01323-5

    authors: Nanou A,Zeune LL,Bidard FC,Pierga JY,Terstappen LWMM

    更新日期:2020-08-12 00:00:00

  • Frequency and spectrum of PIK3CA somatic mutations in breast cancer.

    abstract:PURPOSE:The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, it is currently unknown to what extend this assay detects most PIK3CA mutations in BC. This informati...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01284-9

    authors: Martínez-Sáez O,Chic N,Pascual T,Adamo B,Vidal M,González-Farré B,Sanfeliu E,Schettini F,Conte B,Brasó-Maristany F,Rodríguez A,Martínez D,Galván P,Rodríguez AB,Martinez A,Muñoz M,Prat A

    更新日期:2020-05-13 00:00:00

  • LincIN, a novel NF90-binding long non-coding RNA, is overexpressed in advanced breast tumors and involved in metastasis.

    abstract:BACKGROUND:Recent genome-wide profiling by sequencing and distinctive chromatin signatures has identified thousands of long non-coding RNA (lncRNA) species (>200 nt). LncRNAs have emerged as important regulators of gene expression, involving in both developmental and pathological processes. While altered expression of ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-017-0853-2

    authors: Jiang Z,Slater CM,Zhou Y,Devarajan K,Ruth KJ,Li Y,Cai KQ,Daly M,Chen X

    更新日期:2017-05-30 00:00:00

  • The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells.

    abstract:BACKGROUND:Tumor hypoxia is an independent prognostic factor associated with poor patient survival. Emerging evidence suggests that hypoxia can potentially maintain or enhance the stem cell phenotype of both normal stem cells and cancer cells. However, it remains to be determined whether cell fate is regulated in vivo ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-018-0944-8

    authors: Kim H,Lin Q,Glazer PM,Yun Z

    更新日期:2018-03-06 00:00:00

  • Nongenomic oestrogen signalling in oestrogen receptor negative breast cancer cells: a role for the angiotensin II receptor AT1.

    abstract:INTRODUCTION:Oestrogens can mediate some of their cell survival properties through a nongenomic mechanism that involves the mitogen-activated protein kinase (MAPK) pathway. The mechanism of this rapid signalling and its dependence on a membrane bound oestrogen receptor (ER), however, remains controversial. The role of ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1509

    authors: Lim KT,Cosgrave N,Hill AD,Young LS

    更新日期:2006-01-01 00:00:00

  • Vaccinia virus GLV-1h153 is a novel agent for detection and effective local control of positive surgical margins for breast cancer.

    abstract:INTRODUCTION:Surgery is currently the definitive treatment for early-stage breast cancer. However, the rate of positive surgical margins remains unacceptably high. The human sodium iodide symporter (hNIS) is a naturally occurring protein in human thyroid tissue, which enables cells to concentrate radionuclides. The hNI...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3404

    authors: Gholami S,Chen CH,Belin LJ,Lou E,Fujisawa S,Antonacci C,Carew A,Chen NG,De Brot M,Zanzonico PB,Szalay AA,Fong Y

    更新日期:2013-03-18 00:00:00

  • Correction to: Consistent and reproducible cultures of large-scale 3D mammary epithelial structures using an accessible bioprinting platform.

    abstract::Following publication of the original article [1], the authors reported a typesetting error in the spelling of the second author's name. ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,已发布勘误

    doi:10.1186/s13058-018-1069-9

    authors: Reid JA,Mollica PA,Bruno RD,Sachs PC

    更新日期:2018-11-19 00:00:00